Share:
RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO
™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
ORLADEYO is the first and only prophylactic HAE medication approved in Japan. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
ORLADEYO will be commercialized in Japan by BioCryst s partner, Torii Pharmaceutical Co., Ltd. OrphanPacific, Inc. is BioCryst s representative partner in Japan and holds the marketing authorization.